Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 21908428 
Sohn HW, Krueger PD, Davis RS, Pierce SK (2011) FcRL4 acts as an adaptive to innate molecular switch dampening BCR signaling and enhancing TLR signaling. Blood 118, 6332-41 21908428
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y451-p - FcRL4 (human)
Orthologous residues
FcRL4 (human): Y451‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Downstream Regulation
 Effect of modification (process):  signaling pathway regulation
 Comments:  all 3 sites (Y451, Y463, Y493) inhibits BCR signaling and enhances TLR9 signaling

Y463-p - FcRL4 (human)
Orthologous residues
FcRL4 (human): Y463‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Downstream Regulation
 Effect of modification (process):  signaling pathway regulation
 Comments:  all 3 sites (Y451, Y463, Y493) inhibits BCR signaling and enhances TLR9 signaling

Y493-p - FcRL4 (human)
Orthologous residues
FcRL4 (human): Y493‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  lymphoma, Burkitt's lymphoma
 Relevant cell lines - cell types - tissues:  RAMOS (B lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
Downstream Regulation
 Effect of modification (process):  signaling pathway regulation
 Comments:  all 3 sites (Y451, Y463, Y493) inhibits BCR signaling and enhances TLR9 signaling


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.